Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?

被引：11
|
作者：
Gerard, Alexandre O. [1 ,2 ]
Laurain, Audrey [1 ]
Favre, Guillaume [1 ]
Drici, Milou-Daniel [2 ]
Esnault, Vincent L. M. [1 ]
机构：
[1] Univ Cote Azur, Pasteur Hosp, Nephrol Dialysis Transplantat Dept, Nice, France
[2] Univ Cote Azur, Pasteur Hosp, Dept Pharmacol, Nice, France
来源：
DIABETES CARE | 2022年 / 45卷 / 10期
关键词：
D O I：
10.2337/dc22-0921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E148 / E149
页数：2
相关论文
共 50 条
  • [41] SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond
    Tuttle, Katherine R.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01): : 3 - 5
  • [42] Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Zhao, Li-Min
    Zhan, Ze-Lin
    Ning, Jie
    Qiu, Mei
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [43] Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2020, 59 (08) : 981 - 994
  • [44] Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
    André J. Scheen
    Clinical Pharmacokinetics, 2020, 59 : 981 - 994
  • [45] Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
    Rossing, P.
    Fioretto, P.
    Clark, A.
    Jensen, A. B.
    Nazal, N. Belmar
    Tuttle, K. R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S356 - S357
  • [46] Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform
    Johannes, Catherine B.
    Ziemiecki, Ryan
    Pladevall-Vila, Manel
    Kosvesdy, Csaba P.
    Ebert, Natalie
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    Baak, Brenda
    Robles Cabaninas, Celia
    Kashihara, Naoki
    Yano, Yuichiro
    Kanegae, Hiroshi
    Coleman, Craig I.
    Okami, Suguru
    Liu, Fangfang
    Layton, J. Bradley
    Vizcaya, David
    Oberprieler, Nikolaus G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 237 - 238
  • [47] SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
    Thomas, Merlin C.
    Neuen, Brendon L.
    Twigg, Stephen M.
    Cooper, Mark E.
    Badve, Sunil, V
    ENDOCRINE CONNECTIONS, 2023, 12 (08)
  • [48] Hepatic Effectiveness of SGLT2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
    Bea, Sungho
    Ko, Hwa Yeon
    Shin, Ju-Young
    DIABETES, 2024, 73
  • [49] Safety of SGLT2 inhibitors in elderly patients with diabetic kidney disease
    Reactions Weekly, 2023, 1964 (1) : 11 - 11
  • [50] Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease
    Amioka, Michitaka
    Sanada, Ryuhei
    Matsumura, Hiroya
    Kinoshita, Hiroki
    Sairaku, Akinori
    Morishima, Nobuyuki
    Nakano, Yukiko
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 370 : 294 - 299
12345